Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study

Diabetes Care

Volumn 26, Issue 3, 2003, Pages 777-783

  Goldstein, Irwin ^a   Young, Jay M ^b   Fischer, Jerome ^c   Bangerter, Keith ^d   Segerson, Thomas ^d   Taylor, Terry ^d  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b S Coast Urological Medical Center   (United States)

^c Diabetes and Glandular Disease Clinic   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HEMOGLOBIN A1C; INSULIN; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; VARDENAFIL;

ACCIDENT; ADULT; AMNESIA; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECG ABNORMALITY; ERECTILE DYSFUNCTION; FLUSHING; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; HYPESTHESIA; INSULIN DEPENDENT DIABETES MELLITUS; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SEXUAL INTERCOURSE; ST SEGMENT DEPRESSION; STATISTICAL SIGNIFICANCE; THORAX PAIN; TREATMENT OUTCOME; VISUAL DISORDER;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 0042405173     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.3.777     Document Type: Article

References (16)

1. Lewis R, Hatzichristou D, Laumann E, McKinlay J: Epidemiology and natural history of erectile dysfunction: risk factors including iatrogenic and aging. In Erectile Dysfunction. Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R, Eds. Plymbridge Distributors Ltd, Plymouth, United Kingdom, 2000, p. 21-51.
2. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: prevalence and predictors. JAMA 281:537-544, 1999
3. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentini M, Nicolucci A: Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care 25:284-291, 2002
4. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS: Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 52:848-852, 1998
5. Vinik A, Richardson D: Erectile dysfunction in diabetes. Diabetes Reviews 6:16-33, 1998
6. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, Landoni M, Parazzini F: Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 21:1973-1977, 1998
7. Azadzoi KM, Saenz de Tejada I: Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 148:1587-1591, 1992
8. Ayan S, Yildirim S, Ucar C, Sarioglu Y, Gultekin Y, Butuner C: Corporal reactivity to adenosine and prostaglandin E1 in alloxan-induced diabetic rabbit corpus cavernosum, and the effect of insulin therapy. BJU Int 83:108-112, 1999
9. Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA 281:421-426, 1999
10. Boulton AJ, Selam JL, Sweeney M, Ziegler D: Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 44:1296-1301, 2001
11. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 13:282-290, 2001
12. Bischoff E, Schneider K: A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 13:230-235, 2001
13. Kim NN, Huang YH, Goldstein I, Bischoff E, Traish AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 69:2249-2256, 2001
14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822-830, 1997
15. Hellstrom W, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H: Vardenafil for the treatment of men with erectile dysfunction: efficacy and safety in a randomized double-blind placebo-controlled trial J Androl 23:763-771, 2002
16. Hatzichristou DG: Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 14:S43-S52, 2002